Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?

J Cardiovasc Med (Hagerstown). 2019 Oct;20(10):727-729. doi: 10.2459/JCM.0000000000000825.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aminobutyrates / adverse effects
  • Aminobutyrates / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Biphenyl Compounds
  • Drug Combinations
  • Female
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Neprilysin / antagonists & inhibitors*
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Recovery of Function
  • Retrospective Studies
  • Stroke Volume / drug effects*
  • Tetrazoles / adverse effects
  • Tetrazoles / therapeutic use*
  • Time Factors
  • Time-to-Treatment
  • Treatment Outcome
  • Valsartan
  • Ventricular Function, Left / drug effects*
  • Ventricular Remodeling / drug effects*

Substances

  • Aminobutyrates
  • Angiotensin II Type 1 Receptor Blockers
  • Biphenyl Compounds
  • Drug Combinations
  • Protease Inhibitors
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination